3-MeO-PCMo

Hypertension, coronary artery disease, arrhythmia, or other cardiovascular conditions. NMDA antagonists in the PCP class produce sympathomimetic cardiovascular stimulation that may precipitate acute cardiovascular events.

Concurrent use of CNS depressants including alcohol, opioids, benzodiazepines, and GHB. Every documented fatality involving 3-MeO-PCP included co-ingestion of CNS depressants. Synergistic respiratory depression is the primary acute lethal risk.

Pre-existing seizure disorders or epilepsy. High doses of PCP-site NMDA antagonists may lower seizure threshold, increasing risk of seizure events.

Personal or family history of psychotic disorders. PCP-site NMDA antagonists are established psychotomimetics; acute and persistent psychosis documented following 3-MeO-PCP use. Risk of precipitating or exacerbating psychosis is high across the arylcyclohexylamine class.

Bipolar disorder or history of manic episodes. Mania is an anecdotally reported effect of 3-MeO-PCMo (PsychonautWiki). Individuals with bipolar disorder face elevated risk of precipitated manic episodes.

Significant hepatic impairment. Metabolism is inferred to depend on polymorphic CYP enzymes (CYP2B6, CYP2C19, CYP2D6 based on 3-MeO-PCP data from Michely et al. 2017). Impaired hepatic clearance could result in prolonged and intensified effects.

CYP2D6 poor metabolizer status (approximately 5–10% of Caucasian populations). Potential for substantially prolonged effects and elevated plasma concentrations due to impaired clearance. Inferred from 3-MeO-PCP metabolism data (Michely et al. 2017).

Pregnancy and lactation. No reproductive toxicity data exist for 3-MeO-PCMo. NMDA receptor antagonists disrupt neurodevelopmental processes and are contraindicated during pregnancy as a class.